Patents by Inventor Anthony Jennings
Anthony Jennings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240131264Abstract: Described is an autoinjector comprising of a case, a motor adapted to rotate a drive gear, and a curvi-linear plunger adapted to mate with the drive gear. The plunger includes a distal end with a resilient flange, which in a non-deflected state, abuts a proximal collar of a syringe, and, in a deflected state, advances through the proximal collar and engages a stopper in the syringe.Type: ApplicationFiled: January 4, 2024Publication date: April 25, 2024Inventors: Charley Henderson, David Cross, Douglas Ivan Jennings, Ryan Anthony McGinley
-
Patent number: 11957879Abstract: An autoinjector includes a case configured to receive a syringe, a slidable member that is movable axially within the case to cause at least a portion of the syringe to move axially when the syringe is disposed within the case for dispensing a medicament through a needle of the syringe, a locking member configured to prevent actuation of the slidable member when the autoinjector is in a pre-dispense configuration, a sleeve coupled to a distal end of the case and surrounding at least a portion of a needle of the syringe when the syringe is disposed within the case, an elongate member extending proximally from the sleeve and configured to deflect the locking member to allow actuation of the plunger, and two drive springs coupled to the slidable member and configured to apply a biasing force that acts on the slidable member to move the slidable member distally.Type: GrantFiled: July 6, 2023Date of Patent: April 16, 2024Assignee: Sanofi-Aventis Deutschland GMBHInventors: Charley Henderson, David Cross, Douglas Ivan Jennings, Ryan Anthony McGinley
-
Publication number: 20240077016Abstract: An HHO gas second fuel is produced in a pressure-resistant container and distributed at a low volumetric rate at multiple locations about the internal combustion engine.Type: ApplicationFiled: November 11, 2023Publication date: March 7, 2024Inventors: Evan Charles Johnson, Adam Anthony Filkins, Herbert Daniel Deming, Henry White Dean, Phillip Edward Jennings
-
Publication number: 20230297913Abstract: A system for converting a work procedure document into a mobile application and mobile applications for executing work procedures are disclosed. The conversion system converts work procedure data in the document into a converted format. In some cases, the converted formatted is consumable by a mobile application. The conversion system can be programmed to identify steps and sub-steps in the work procedure based on business-specific formatting characteristics common to work procedure documents. The mobile application can be configured to generate a controlled workflow for a work procedure on a mobile device. The workflow can prompt a user to provide inputs to the mobile device indicating performance of steps in the work procedure.Type: ApplicationFiled: September 28, 2022Publication date: September 21, 2023Inventors: Anthony Jennings, Nathan Boosinger, Matthew Johnson
-
Patent number: 11345736Abstract: The present disclosure relates to multi-specific molecules which are capable of simultaneously binding at least two different target antigens or epitopes. The molecules comprise at least one binding domain molecule (BDM) which hinds to a first target antigen or epitope, the BDM being modified for selective binding to a heterologous target, coupled to a pharmacologically active protein or peptide which is an antibody or antigen-binding fragment thereof or a non-antibody protein or peptide which binds to a second target antigen or epitope, the BDMs being coupled to a C-terminus of a polypeptide present within the pharmacologically active protein or peptide.Type: GrantFiled: April 6, 2021Date of Patent: May 31, 2022Assignee: IMUNEXUS THERAPEUTICS LIMITEDInventors: Anthony Simon Roberts, George Kopsidas, Michael Ross Luke, Phil Anthony Jennings
-
Publication number: 20210347904Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: ApplicationFiled: September 24, 2020Publication date: November 11, 2021Inventors: Lynn Dorothy POULTON, Adam CLARKE, Andrew James POW, Debra TAMVAKIS, George KOPSIDAS, Anthony Gerard DOYLE, Philip Anthony JENNINGS, Matthew POLLARD
-
Publication number: 20210230249Abstract: The present disclosure relates to multi-specific molecules which are capable of simultaneously binding at least two different target antigens or epitopes. The molecules comprise at least one binding domain molecule (BDM) which hinds to a first target antigen or epitope, the BDM being modified for selective binding to a heterologous target, coupled to a pharmacologically active protein or peptide which is an antibody or antigen-binding fragment thereof or a non-antibody protein or peptide which binds to a second target antigen or epitope, the BDMs being coupled to a C-terminus of a polypeptide present within the pharmacologically active protein or peptide.Type: ApplicationFiled: April 6, 2021Publication date: July 29, 2021Inventors: Anthony Simon ROBERTS, George KOPSIDAS, Michael Ross LUKE, Phil Anthony JENNINGS
-
Publication number: 20210040177Abstract: The present disclosure relates to multi-specific molecules which are capable of simultaneously binding at least two different target antigens or epitopes. The molecules comprise at least one binding domain molecule (BDM) which binds to a first target antigen or epitope, the BDM being modified for selective binding to a heterologous target, coupled to a pharmacologically active protein or peptide which is an antibody or antigen-binding fragment thereof or a non-antibody protein or peptide which binds to a second target antigen or epitope, the BDMs being coupled to a C-terminus of a polypeptide present within the pharmacologically active protein or peptide.Type: ApplicationFiled: June 22, 2020Publication date: February 11, 2021Inventors: Anthony Simon ROBERTS, George KOPSIDAS, Michael Ross LUKE, Phil Anthony JENNINGS
-
Patent number: 10822422Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: GrantFiled: July 11, 2016Date of Patent: November 3, 2020Assignee: Teva Pharmaceuticals Australia Pty LtdInventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
-
Publication number: 20200034770Abstract: A system for converting a work procedure document into a mobile application and mobile applications for executing work procedures are disclosed. The conversion system converts work procedure data in the document into a converted format. In some cases, the converted formatted is consumable by a mobile application. The conversion system can be programmed to identify steps and sub-steps in the work procedure based on business-specific formatting characteristics common to work procedure documents. The mobile application can be configured to generate a controlled workflow for a work procedure on a mobile device. The workflow can prompt a user to provide inputs to the mobile device indicating performance of steps in the work procedure.Type: ApplicationFiled: July 24, 2019Publication date: January 30, 2020Applicant: Ameren CorporationInventors: Anthony Jennings, Nathan Boosinger, Matthew Johnson
-
Publication number: 20190338013Abstract: The present disclosure relates to multi-specific molecules which are capable of simultaneously binding at least two different target antigens or epitopes. The molecules comprise at least one binding domain molecule (BDM) which binds to a first target antigen or epitope, the BDM being modified for selective binding to a heterologous target, coupled to a pharmacologically active protein or peptide which is an antibody or antigen-binding fragment thereof or a non-antibody protein or peptide which binds to a second target antigen or epitope, the BDMs being coupled to a C-terminus of a polypeptide present within the pharmacologically active protein or peptide.Type: ApplicationFiled: February 27, 2017Publication date: November 7, 2019Inventors: George KOPSIDAS, Michael Ross LUKE, Phil Anthony JENNINGS, Anthony Simon ROBERTS
-
Publication number: 20160333104Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: ApplicationFiled: July 11, 2016Publication date: November 17, 2016Inventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
-
Publication number: 20160264661Abstract: Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12R?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.Type: ApplicationFiled: April 22, 2016Publication date: September 15, 2016Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Hoi Yi Wai, Andrew James Pow, George Kopsidas
-
Publication number: 20140255302Abstract: The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.Type: ApplicationFiled: March 28, 2014Publication date: September 11, 2014Applicant: Teva Pharmaceuticals Australia Pty LtdInventors: Lynn Dorothy Poulton, Adam Clarke, Andrew James Pow, Debra Tamvakis, George Kopsidas, Anthony Gerard Doyle, Philip Anthony Jennings, Matthew Pollard
-
Publication number: 20140086922Abstract: Provided herein is an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80), and the antibody inhibits the binding of human IL-12 to human IL-12R?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.Type: ApplicationFiled: September 18, 2013Publication date: March 27, 2014Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow, George Kopsidas
-
Patent number: 8563697Abstract: The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R ?2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R?1.Type: GrantFiled: August 14, 2009Date of Patent: October 22, 2013Assignee: Cephalon Australia Pty. Ltd.Inventors: Adam William Clarke, Anthony Gerard Doyle, Philip Anthony Jennings, Lynn Dorothy Poulton, Bernadette Wai, Andrew James Pow, George Kopsidas
-
Publication number: 20110319597Abstract: The present invention relates to domain antibodies which have modified framework regions such that the potency or level of binding of the domain antibody is improved. In particular the present invention relates to domain antibodies which bind TNFa in which changes have been made to framework sequences and to constructs including these domain antibodies.Type: ApplicationFiled: August 13, 2009Publication date: December 29, 2011Applicant: Caphalon Australia Pty. Ltd.Inventors: Raina Jui Yu Simpson, Zehra Elgundi, Anthony Gerard Doyle, Philip Anthony Jennings, Robert Daniel Gay, Adam William Clarke
-
Publication number: 20100040620Abstract: The present invention provides a binding complex comprising antibodies or antigen-binding fragments which bind to both Lewisy and Lewisb antigens, wherein the antibodies or antigen-binding fragments are in the form of multimers, and wherein the antibodies or antigen-binding fragments do not naturally form multimers.Type: ApplicationFiled: September 20, 2007Publication date: February 18, 2010Inventors: Linda Gillian Durrant, Philip Anthony Jennings
-
Publication number: 20040132121Abstract: The present invention relates to peptides having eubacterial b protein-binding properties and the surface of b protein with which said peptides and other proteins interact. The invention provides in vitro and in vivo assays for identifying compounds that modulate the interaction between b protein and proteins that interact therewith, and a method of controlling eubacterial infestation by modulating this interaction. The disclosed peptides can be used as templates for the design or selection of compounds that modulate the foregoing interaction.Type: ApplicationFiled: November 10, 2003Publication date: July 8, 2004Inventors: Brian Paul Dalrymple, Kritaya Kongsuwan, Gene-Louise Wilfiels, Philip Anthony Jennings, Gregory William Komp
-
Patent number: 6365730Abstract: The invention describes catalytic nucleic acid based compounds capable of cleaving nucleic acid polymers both in vivo and in vitro. Two embodiments of this invention are compounds with a short stem that does not base pair, a minizyme, and compounds with DNA hybridizing arms and RNA catalytic domain and stem, DNA-armed ribozymes. The compounds of this invention, while nucleotide based may be substituted or modified in the sugar, phosphate, or base. Methods of use and methods of treatment are also described.Type: GrantFiled: December 8, 1992Date of Patent: April 2, 2002Assignee: Gene Shears Pty. LimitedInventors: Philip Anthony Jennings, Maxine June McCall, Philip Hendry